Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV.
Although antiretroviral therapies have been effective in decreasing active viral loads in AIDS patients, the persistence of latent viral reservoirs prevents eradication of the virus. Prostratin and DPP (12-deoxyphorbol-13-phenylacetate) activate the latent virus and thus represent promising adjuvants for antiviral therapy. Their limited supply and the challenges of accessing related structures have, however, impeded therapeutic development and the search for clinically superior analogs. Here we report a practical synthesis of prostratin and DPP starting from phorbol or crotophorbolone, agents readily available from renewable sources, including a biodiesel candidate. This synthesis reliably supplies gram quantities of the therapeutically promising natural products, hitherto available only in low and variable amounts from natural sources, and opens access to a variety of new analogs.
Wender
Paul A
PA
Department of Chemistry, Stanford University, 337 Campus Drive, Stanford, CA 94305, USA. wenderp@stanford.edu
Kee
Jung-Min
JM
Warrington
Jeffrey M
JM
D019380:Anti-HIV Agents / Q000138:chemical synthesis*; D017024:Chemotherapy, Adjuvant; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008958:Models, Molecular; D010703:Phorbol Esters / Q000138:chemical synthesis*; D010704:Phorbols / Q000737:chemistry; D019562:Viral Load; D017735:Virus Latency / Q000187:drug effects
D019380:Anti-HIV Agents; D010703:Phorbol Esters; D010704:Phorbols; C029704:12-deoxyphorbolphenylacetate; C070999:prostratin; C033085:phorbol